Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

52 results about "Posttraumatic stress disorders" patented technology

Application of 2-arylimidazo[1,2-alpha]pyridine-3-acetamide derivative to prepare medicines for controlling PTSD

The invention belongs to the field of medicinal chemical engineering, and relates to application of 2-arylimidazo[1,2-alpha]pyridine-3-acetamide derivatives to prepare medicines for controlling PTSD (posttraumatic stress disorder). Specifically, the invention relates to application of a compound shown as a formula I and pharmaceutically salts thereof to prepare medicines for controlling and / or treating and / or auxiliarily treating PTSD, wherein the compound and the pharmaceutically salts thereof are used as TSPO (translocator protein) ligands. The TSPO ligands such as the compounds shown as the formula I and the pharmaceutically salts are capable of effectively preventing and / or treating and / or auxiliarily treating PTSD, and can be used to prevent medicines for controlling and / or treating and / or auxiliarily treating PTSD.
Owner:INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A

Combination of atypical antipsychotics and 5HT-1B receptor antagonists

InactiveUS20050256112A1Reduce morbidityDifferent recognizableNervous disorderMetabolism disorderDiseaseHeadaches
The present invention relates to a pharmaceutical composition for treating, for example, a disorder or condition selected from the group consisting of hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress disorder, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, preferably a human, comprising (i) an atypical antipsychotic or a pharmaceutically acceptable salt thereof, (ii) a 5-HT1B receptor antagonist or a pharmaceutically acceptable salt thereof, wherein the 5-HT1B receptor antagonist is selected from the group consisting of (A) a compound of the formula I as described in the specification and (B) a compound of the formula II as described in the specification, and optionally (iii) a pharmaceutically acceptable carrier.
Owner:PFIZER INC

Device, system, and method for treating psychiatric disorders

Provided are a device, system, and method for treating a patient having posttraumatic stress disorder (PTSD) or other such psychiatric disorder. An event being recounted by the patient is recorded and a sensory environment of the patient is controlled so as to administer exposure therapy to the patient. Patient mental state may be monitored during administration of the exposure therapy to the patient, and the exposure therapy may be varied in correspondence to the monitored mental state of the patient. In one embodiment, hierarchy assembly means creates a treatment hierarchy based on input from the patient, and hierarchy navigation means navigates within the treatment hierarchy in response to the mental state of the patient.
Owner:THE EVERMIND GRP LLC

Virtual reality therapy system for driving posttraumatic stress disorder

InactiveCN103405239AAvoid psychological harmImprove securityDiagnostic recording/measuringSensorsVirtual reality therapyDisplay device
The invention provides a virtual reality therapy system for driving posttraumatic stress disorder. The virtual reality therapy system comprises a helmet display, a sound effect system, a driving console, a multichannel physiological monitoring device and a controller, wherein the helmet display is used for displaying a virtual scene, the sound effect system is used for outputting an audio signal matched with the virtual scene, the driving console is matched with the virtual scene, and the multichannel physiological monitoring device is used for monitoring physiological data of a user in real time. The virtual reality therapy system for the driving posttraumatic stress disorder is high in safety, remarkable in effect, high in controllability and short in therapy time.
Owner:QINGDAO CYBERCARE INFORMATION TECH

Novel pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders

Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and alprazolam are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from one or more psychiatric disorders such as major depressive disorder, generalized anxiety disorder, panic disorder, agitation, social anxiety disorder, mild chronic depression, obsessive-compulsive disorder, premenstrual dysphoric disorder, seasonal affective disorder, dysthymia, childhood enuresis, bipolar disorder, posttraumatic stress disorder, sleep disorder related to anxiety, are also disclosed.
Owner:LA PHARMATECH INC

Steroide anionic compounds, method of their production, usage and pharmaceutical preparation involving them

A compound with general formula Ifor treatment of various diseases of the central nervous system, in treatment of neuropsychiatric disorders related to imbalance of glutamatergic neurotransmitter system, ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, PTSD and other diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addictions, multiple sclerosis, epilepsy and gliomas.
Owner:USTAV ORGANICKE CHEM A BIOCHEM AKADE VED CR V V I +2

Soldier wearable self-adaptation auxiliary treatment system based on artificial intelligence

ActiveCN108939248AIncrease the severityFlexible treatmentDiagnostic recording/measuringSensorsTreatment effectPhysiological monitoring
The invention discloses a soldier wearable self-adaptation auxiliary treatment system based on artificial intelligence. A war simulating system, a physiological monitoring system and a self-adaption treatment system are set; battlefield simulation is carried out on a soldier through the war simulating system, the soldier can feel true scenes in a war, the physiological monitoring system monitors the physiological reaction generated when the soldier encounters the situation, and if data exception occurs, the self-adaption treatment system is adopted for carrying out relaxing treatment on the soldier; pictures which are not too irritative can be firstly presented during treatment, the horrifying degree of the pictures is gradually increased, and the soldier is made to accept various situations possibly happening on the battlefield step by step. The soldier wearable self-adaptation auxiliary treatment system can be suitable for soldier readaptation before the war and can also be suitablefor posttraumatic stress disorder of the soldier after the war, the treatment modes are flexible and diversified, the site simulation trueness is high, and the system has a good treatment effect on psychological counseling of the soldier before the war and posttraumatic stress disorder of the soldier after the war.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Heteroaryl-pyrazole derivative

A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.
Owner:TAISHO PHARMACEUTICAL CO LTD

Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors

InactiveUS20050197337A1Valuable therapeutic propertyBiocideNervous disorderMuscular spasticityPosttraumatic stress disorders
The present invention relates to compounds of formula whereinX is —S— or —NH—; R3 / R4 together with the N-atom to which they are attached form a non aromatic 5, 6 or 7 membered ring, which optionally contains in addition to the N-atom one additional heteroatom selected from the group consisting of O, S and N, and wherein the ring is optionally substituted by hydroxy, lower alkyl, lower alkoxy, —NR2, —CONR2, —CO-lower alkyl or benzyl; or R3 / R4 form together with the N-atom to which they are attached a heterocyclic ring system, containing two or three rings and which optionally contains one or two additional heteroatoms selected from the group consisting of N and O and which has no more than 20 carbon atoms; andR, R1, R2, and R5 are as defined herein and to pharmaceutically suitable acid addition salts thereof. It has been found that the compounds of the invention are active on the GABAB receptor and therefore are useful for the treatment of anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, psychosis, panic disorder, posttraumatic stress disorders and gastro-intestinal disorders.
Owner:F HOFFMANN LA ROCHE & CO AG

Deficiency-tonifying tranquilizing pill

InactiveCN103520678AAvoid the situation where you are easily attacked by external wind and evil and then become sickRelieve muscle tensionNervous disorderInanimate material medical ingredientsPhysiologyOyster
The invention discloses a deficiency-tonifying tranquilizing pill, and belongs to the technical field of Chinese patent medicines. The deficiency-tonifying tranquilizing pill comprises the traditional Chinese medicines according to the following components and formula: 4 parts of poria cocos, 5 parts of poria with hostwood, 3 parts of cassia twig, 2 parts of honey-fried licorice root, 2 parts of hangzhou white peony, 2 parts of dried ginger, 1 parts of keel, 1 parts of raw oysters, 1 parts of ophiopogon japonicas, 2 parts of polygala root, 2 parts of sun-dried ginseng, 4 parts of jujube and 1 part of saposhnikovia divaricata. The deficiency-tonifying tranquilizing pill provided by the invention has good control effects on body and mind responding symptoms caused by posttraumatic stress disorder, wherein the body and mind responding symptoms comprise spirit fatigue, strength lack, insomnia, irritability, too high vigilant intensity, muscular tension, excessive scare, dreaminess and the like.
Owner:张桂赫

Application of adenosine compound in preparation of drugs for prevention and treatment of stress disorders

ActiveCN104173363AAlleviate and/or treat anxiety disordersAlleviate and/or treat maniaOrganic active ingredientsNervous disorderAcute Stress DisorderApoptosis
The invention discloses application of an adenosine compound WS070133 shown as formula I in preparation of products for prevention or treatment of stress disorders. The stress disorders and related diseases include acute stress disorder, posttraumatic stress disorder, adjustment disorder and phobia, anxiety, mania, bipolar disorder and other diseases. Oral administration of WS070133 on posttraumatic stress disorder model animals shows that the adenosine compound has the effects of lowering animal stress level, reducing fear, anxiety like symptoms and learning and memory impairment. Study also shows that WS070133 can lower the corticosterone level and excitatory amino acid content, reduce apoptosis of neurons and has a regulation effect on related protein molecules. WS070133 has the advantages of low toxicity, no dependence, metabolic and addiction, quick metabolic clearance and no residual effect, etc., thus havaing good application and development prospects. (formula I).
Owner:INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI

Pharmaceutical composition for treating posttraumatic stress disorder

Provided are a posttraumatic stress disorder (PTSD) animal model in which dopamine receptor subtype 4 (D4R) is damaged or deficient, a method for preparing the same, a method for screening a drug for treating PTSD using the same, and a pharmaceutical composition for treating PTSD comprising a drug detected by the screening method. As it is identified that a specific type of dopamine receptor is associated with a mechanism for fear memory expression induced by long-term depression (LTD), the understanding of pathogenesis of PTSD may be heightened, the animal model exhibiting similar clinical conditions of PTSD and the method for preparing the same may be applied in analyses for stability and effectiveness of a therapeutic agent for PTSD and screening of a therapeutic drug. Further, an agonist of D4R contained in the composition has been approved by the US FDA and clinically used for psychiatric diseases such as schizophrenia, and thus may be immediately used for clinical applications for PTSD symptoms.
Owner:POSTECH ACAD IND FOUND

Application of doxycycline in preparing medicines for enhancing PAC1-R (Pituitary Adenylate Cyclase Activating Polypeptide Type 1 Receptor) dimer dependent constitutive activity

InactiveCN103393700AEnhanced intrinsic activityNervous disorderTetracycline active ingredientsDimerDisease
The invention discloses an application of doxycycline for preparing medicines for enhancing PAC1-R (Pituitary Adenylate Cyclase Activating Polypeptide Type 1 Receptor) dimer dependent constitutive activity. The doxycycline is used as a B type G-protein-coupled receptor PAC1-R dimmer for enhancing the PAC1-R dimer dependent constitutive activity so as to exert the biological functions through a PAC1-R mediated signal transduction pathway. As PAC1-R is a specific receptor of neuropeptide PACAP (Pituitary Adenylate Cyclase Activating Polypeptide), and PAC1-R mediates various important biological functions, so that the activity of the doxycycline to the PAC1-R dimer indicates that the doxycycline can be applied to treatment and medicinal development of diseases taking PAC1-R as target spots, for example, memory impairment, oligospermia, asthenozoospermia, posttraumatic stress disorder and the like.
Owner:余榕捷

Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders

InactiveUS20140249090A1Increase alertnessNervous disorderPeptide/protein ingredientsPanicGeneralised anxiety disorder
The present invention provides peptides for use in a medicament which is administered nasally, wherein the peptide is an agonist of neuropeptide S receptor (NPSR), of the receptor TGR23 and / or of vasopressin receptor-related receptor 1 (VRR1) or for use in the treatment of a patient by causing, promoting or increasing relieve or healing of phobic anxiety, avoidance anxiety, dissociative anxiety such as flashbacks, depersonalization, derealization, intrusions, vegetative symptoms related to anxiety symptoms, especially in panic attacks, in posttraumatic stress disorder, in generalised anxiety disorder and in anxiety accompanying depressive, or psychotic episodes, arousal, awakening, alertness, activity, spontaneous movement, an anxiolytic effect or a combination thereof in the patient, wherein the peptide is administered nasally or for use in the prophylaxis and / or treatment of an anxiety or sleep disorder, especially in any type of hypersomnia like idiopathic hypersomnia, wherein the peptide is administered nasally. Further provided are pharmaceutical compositions for nasal administration comprising at least one of said peptides, uses of said peptide or said pharmaceutical composition. The invention also provides a method for identifying target neurons of a peptide in an animal, wherein the peptide is administered nasally.
Owner:MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV

5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression

Provided are compositions for use in treating a patient suffering from a mental disorder in particular major depressive disorder, persistent depressive disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder and psychoactive substance abuse. Further provided are dosing regimens for treating these disorders.
Owner:GH RES IRELAND LTD

Pharmaceutical composition containing glur2-lacking ampar antagonist for preventing or treating psychiatric illnesses

InactiveUS20110105622A1Preventing and treating mental diseaseDecreased neural activityBiocideOrganic active ingredientsBULK ACTIVE INGREDIENTActive ingredient
A pharmaceutical composition, comprising a GluR2-lacking AMPAR antagonist as an active ingredient, is effective for preventing or treating mental diseases selected from the group consisting of posttraumatic stress disorder (PTSD), drug addiction, and phobia.
Owner:SEOUL NAT UNIV R&DB FOUND

Method and apparatus for predicting posttraumatic behavior problem

Provided is a method and apparatus for predicting a posttraumatic behavior problem that may predict a posttraumatic violent behavior problem of an individual, in detail, that may determine a biological phenotype of an individual experiencing a traumatic event within a predetermined period after the individual is exposed to the traumatic event, predict a violent symptom presentation probability of the individual based on the biological phenotype of the individual, and suggest an objective basis for preventive intervention in a development of posttraumatic stress disorder (PTSD) of the individual based on a prediction result.
Owner:EWHA UNIV IND COLLABORATION FOUND

Ingestible compositions system and method

The ingestible compositions system includes the co-production of orally-ingestible compositions usable as inhalable respiratory agents including delivery apparatus and related methods. The invention comprises a healthy alternative delivery system to smoking. THC / CBD fits like a key in a lock into CB1 and CB2 receptors. The H2O solution (with THC / CBD) can also be consumed orally for a slight euphoric effect. As designed, the present invention can be useful in treating cancers, acute ischemic neurological insults or chronic neurodegenerative diseases, Crohn's disease, Lupus, and PTSD, but is not limited to just the mentioned diseases / ailments.
Owner:FORDE TANIA

1-heteroaryl-indoline-4-carboxamides as modulators of GPR52 useful for the treatment or prevention of disorders related thereto

The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of GPR52. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a GPR52-mediated disorder (e.g., Huntington's disease, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder (ADHD), or Tourette's syndrome); an extrapyramidal or movement disorder; a motor disorder; a hyperkinetic movement disorder; a psychotic disorder; catatonia; a mood disorder; a depressive disorder; an anxiety disorder; obsessive-compulsive disorder (OCD); an autism spectrum disorder; a prolactin-related disorder (e.g., hyperprolactinemia); a neurocognitive disorder; a trauma- or stressor-related disorder (e.g., posttraumatic stress disorder (PTSD)); a disruptive, impulse-control, or conduct disorder; a sleep-wake disorder; a substance-related disorder; an addictive disorder; a behavioral disorder; hypofrontality; an abnormality in the tuberoinfundibular, mesolimbic, mesocortical, or nigrostriatal pathway; decreased activity in the striatum; cortical dysfunction; neurocognitive dysfunction; and conditions related thereto.
Owner:ARENA PHARMA

Reminiscence therapy and media sharing platform

InactiveUS20210313041A1Highly labor-intensiveTime-consume for caregiverMedical communicationAnimal housingMediaFLOAnxiety reduction
Described are reminiscence therapy and media sharing platform, methods, and systems for a patient user which provide an immediate and First Mobile Application positive impact on emotional functioning inpatients with dementia, major neurocognitive disorders, social isolation, traumatic brain injury (TBI), and psychiatric conditions such as posttraumatic stress disorder, by reducing anxiety, depression, and overall emotional distress.
Owner:DTHERA SCI OPERATIONS INC +1

Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders

The use of a phosphatase inhibitor in conjunction with psychotherapy provides enhanced therapeutic results in the treatment of psychiatric disorders including, for example, specific phobias, panic disorders, anxiety disorders including posttraumatic stress disorders, and obsessive-compulsive disorder.
Owner:MERCK & CO INC

Pharmaceutical compositions and methods for treatment of psychiatric disorders

Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and folic acid or folate, and / or salts, metabolites, or derivatives thereof are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from one or more psychiatric disorders or symptoms, such as major depressive disorder, generalized anxiety disorder, panic disorder, agitation, social anxiety disorder, mild chronic depression, obsessive-compulsive disorder, premenstrual dysphoric disorder, seasonal affective disorder, dysthymia, bipolar disorder, posttraumatic stress disorder, sleep disorder related to anxiety, are also disclosed.
Owner:LA PHARMATECH INC

Novel quinoline-4-carboxamide derivative, preparation method thereof, pharmaceutical composition containing novel quinoline-4-carboxamide derivative, and medical application of novel quinoline-4-carboxamide derivative

The invention discloses a compound as shown in a formula I, a pharmaceutical salt or solvate and preparation method of the compound and application of the compound as a drug for preventing or treating posttraumatic stress disorder, anxiety and depressive disorder. In the formula I, R1, R2 and R3 are respectively and independently selected from hydrogen, a halogen atom, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, arylalkyl, substituted arylalkyl, formamyl, substituted formamyl, a naphthenic base, a substituted naphthenic base, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and substituted heteroarylalkyl; and L is a C1-C4 alkyl chain or a C1-C4 olefin chain, wherein the C1-C4 olefin chain contains cis and trans isomers.
Owner:CHENGDU MILITARY GENERAL HOSPITAL OF PLA

Application of total glycosides of Cynanchum otophyllum Schneid to pharmacy

InactiveCN106727811AEnhanced startle reflexIncreased sleep disturbanceNervous disorderCapsule deliveryPharmacyClinical psychology
Total glycosides of Cynanchum otophyllum Schneid can improve rats' chronic social frustration stress and chronic unpredictable mild stress model animal's symptoms, can improve high arousal behaviors of model animals' posttraumatic stress disorder in rats, and can be used in preparation of a medicine for treating and preventing chronic affective disorder and posttraumatic stress disorder.
Owner:GUIZHOU NORMAL UNIVERSITY

Therapeutic Treatment Systems and Processes for Stress-Related Disorders

InactiveUS20120179003A1Enhance existing treatmentAvoid dysfunctionDiagnostic recording/measuringSensorsDiseaseStress-related disorders
A process and automated computer process implemented system are provided to transform therapy and intercranial processes as an aid in therapeutically treating incidents of stress-related disorders such as PTSD or other aspects. Effects may be indicated and assessed by determining a level of concentrated emotional presentness and / or a level of emotional intensity or the like. Various embodiments can provide guidance to both subjects and counselors and can automatically indicate progress or optimal therapies to be used so that a subject, perhaps including but not limited to combat veterans and others who have experienced or been subjected to a stressful situation perhaps characterized by a fight or flight basal reaction. Through the system, subjects can be encouraged to obtain and continue treatment and may more rapidly progress with treatment by being aware of a level of emotional presentness and / or emotional intensity that are incidents of intense stress-related experiences.
Owner:FABER GROUP SYNERGY

Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors

The present invention relates to compounds of formulawhereinX is —S— or —NH—;R3 / R4 together with the N-atom to which they are attached form a non aromatic 5, 6 or 7 membered ring, which optionally contains in addition to the N-atom one additional heteroatom selected from the group consisting of O, S and N, and wherein the ring is optionally substituted by hydroxy, lower alkyl, lower alkoxy, —NR2, —CONR2, —CO-lower alkyl or benzyl; or R3 / R4 form together with the N-atom to which they are attached a heterocyclic ring system, containing two or three rings and which optionally contains one or two additional heteroatoms selected from the group consisting of N and O and which has no more than 20 carbon atoms; andR, R1, R2, and R5 are as defined herein and to pharmaceutically suitable acid addition salts thereof.It has been found that the compounds of the invention are active on the GABAB receptor and therefore are useful for the treatment of anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, psychosis, panic disorder, posttraumatic stress disorders and gastro-intestinal disorders.
Owner:F HOFFMANN LA ROCHE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products